Citizens JMP has initiated coverage on MBX Biosciences (MBX, Financial), assigning an Outperform rating and setting a price target of $38. The firm highlights MBX's innovative approach, leveraging its proprietary Precision Endocrine Peptide platform to advance peptide therapeutics. This strategy is particularly focused on addressing significant unmet needs in the treatment of hypoparathyroidism.
Analysts are drawing attention to upcoming data from a Phase 2 trial, anticipated to be a major catalyst for MBX stock in the third quarter. Additionally, the firm predicts valuable "derisking data" from two other development candidates by 2026, which could further strengthen the company's position in the market.
